Phase II/III study of M606102 in the treatment of axillary hyperhidrosis

The once daily application of M606102 for 4 weeks was effective for the patients with primary axillary hyperhidrosis. The incidences of drug-related adverse events and significant adverse events were high in a dose-dependent manner, but most of the adverse events were mild in severity, the incidence of adverse events leading to discontinuation, interruption, or reduction of study treatment was low, and local skin irritation was rarely observed; the study treatment was considered well tolerated.